Takeda Pharmaceutical Company Limited (TAK)
| Market Cap | 44.28B |
| Revenue (ttm) | 29.28B |
| Net Income (ttm) | 1.89B |
| Shares Out | 3.10B |
| EPS (ttm) | 1.08 |
| PE Ratio | 13.20 |
| Forward PE | 10.22 |
| Dividend | $0.40 (2.78%) |
| Ex-Dividend Date | n/a |
| Volume | 2,593,767 |
| Open | 14.24 |
| Previous Close | 14.35 |
| Day's Range | 14.20 - 14.32 |
| 52-Week Range | 13.17 - 17.56 |
| Beta | 1.00 |
| Analysts | Buy |
| Price Target | 16.11 (+12.8%) |
| Earnings Date | May 10, 2022 |
About TAK
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia...
Financial Performance
In 2020, TAK's revenue was 3.20 trillion, a decrease of -2.84% compared to the previous year's 3.29 trillion. Earnings were 376.01 billion, an increase of 749.90%.
Financial numbers in millions JPYFinancial StatementsAnalyst Forecast
According to 20 analysts, the average rating for TAK stock is "Buy." The 12-month stock price forecast is 16.11, which is an increase of 12.82% from the latest price.
News
Japan's Takeda Pharma says full-year profit slid 9.5%
Takeda Pharmaceutical Co said on Wednesday that 12-month operating profit slid 9.5% from the previous year.
Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for fiscal year 2021 (period ended March 31, 2022), driven by the performance of its growth products,...
Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company top honors in th...
Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hosp...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present four company-sponsored abstracts at the Tandem Transplantation & Cellular The...
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfa...
Takeda's TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Age...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced TAKHZYRO® (lanadelumab-flyo) injection single-dose prefilled syringe is now available in the U.S. to prevent attacks of here...
Takeda Announces Completion of Acquisition of Own Shares
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today provided an update on the status and announced the completion of the acquisition of its own sh...
Takeda's TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the Phase 3 SHP643-301 study (NCT04070326) evaluating the safety profile and pharmacokinetics (PK) of TA...
Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda and the New York Academy of Sciences announced the winners of the fourth Innovators in Science Award.
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced that its Board of Directors will propose two new candidates for independent external directors at the 146th Ordinary Meeting o...
Takeda's TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) for TAKHZYRO® (lanadelum...
3 Japanese Stocks to Diversify Your Portfolio
Japan has the world's third-largest economy, which has started to rebound from the pandemic. The Japanese economy expanded at a 5.4% annualized rate in the fourth quarter of 2021.
Takeda Pharma: A Japanese Dividend Powerhouse
Takeda Pharmaceutical ( TAK , Financial) is Japan's largest R&D-focused biopharma company. Founded in 1781, this is an established company with a global presence.
Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioe...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--AAAAI Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients
Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of Alofisel (darvadstrocel). The stu...
Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analys...
OSAKA, Japan & CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the first six-month interim analysis results from INSPIRE, in which clinical remission* was observed ...
Resilience Establishes Multi-Product Development and Manufacturing Collaboration with Takeda's Plasma-Derived Therapi...
SAN DIEGO--(BUSINESS WIRE)--National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines, today announced a manufacturing servic...
Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Reflecting Strong Momentum
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the third quarter of its fiscal year 2021 (period ended December 31, 2021) driven by robust topli...
FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder
The FDA has approved Takeda Pharmaceutical Co Ltd's TAK Vonvendi [von Willebrand factor (Recombinant)] for routine prophylaxis to reduce the frequency of bleeding episodes in Type 3 von Willebrand disea...
FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living wi...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food & Drug Administration (FDA) approved VONVENDI® [von Willebrand ...
2 Dirt-Cheap Value Stocks to Buy Now
These two dividend-paying pharma stocks ought to be top performers in 2022.
T. Rowe Price Japan Dumps Takeda Holding in 4th Quarter
The T. Rowe Price Japan Fund (Trades, Portfolio), part of Baltimore-based T.
3 Healthcare Stocks With High Dividends
Looking for a healthcare stock that will pay you to own it? Here are three suggestions.
Takeda Named Global Top Employer for Fifth Consecutive Year
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it was one of only 11 companies to achieve global Top Employer...
Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P. Morgan Healthca...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today confirmed the company is positioned for growth in the mid- and long-term with...